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Abstract
Subtype 2 Serotonin (5-Hydroxytryptamine, 5-HT) receptors are major drug targets for
schizophrenia, feeding disorders, perception, depression, migraines, hypertension, anxiety,
hallucinogens, and gastrointestinal dysfunctions.1 We report here the predicted structure of 5-
HT2B and 5-HT2C receptor bound to highly potent and selective 5-HT2B antagonist PRX-08066
3, (pKi: 30 nM), including the key binding residues [V103 (2.53), L132 (3.29), V190 (4.60), and
L347 (6.58)] determining the selectivity of binding to 5-HT2B over 5-HT2A. We also report
structures of the endogenous agonist (5-HT) and a HT2B selective antagonist 2 (1-
methyl-1-1,6,7,8-tetrahydropyrrolo[2,3-g]quinoline-5-carboxylic acid pyridine-3-ylamide). We
examine the dynamics for the agonist-bound and the antagonist-bound HT2B receptors in explicit
membrane and water finding dramatically different patterns of water migration into the NPxxY
motif and the binding site that correlates with the stability of ionic locks in the D(E)RY region
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INTRODUCTION
Three 5-HT2 receptors (2A, 2B, 2C) are major drug targets for schizophrenia, feeding
disorders, perception, depression, migraines, hypertension, anxiety, hallucinogens, and
gastrointestinal dysfunctions, but in many cases it is desirable to bind selectively to just one
of these very similar receptors. 1 These 5-HT2 receptors are highly homologous with ~ 80%
amino acid identity in the transmembrane (TM) domain, so that many 5-HT receptor
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antagonists (e.g., methylsergide, metergoline, mianserin, and ritanserin) have similar
affinities for all three 5-HT2 receptor subtypes.2 Unfortunately, there is a paucity of
antagonists selective for the 5-HT2B or 2C receptors, leading to cross-selectivity for drugs
targeting either receptor.
Previously, we reported the predicted the 3-Dimensional (3D) structure for human 5-HT2C
receptors (hHT2CR) using the MembStruk computational procedure.3 Based on this
structure, we used the MSCDock computational procedure to predict the 3-D structures for
bound ligand-protein complexes for agonists such as serotonin and antagonists such as
ritanserin, metergoline, and methiothepin. The predicted structure-activity relationship
(SAR) data for a series of psilocybin analogs, both agonists and antagonists shows a good
agreement with the currently known experimental data.
Here, we report the new predicted structures of human 5-HT2B receptors (hHT2BR) and
hHT2CR using newer methods, the MembEnsemb and the GenMSCDock techniques. To
understand the subtype selectivity of hHT2BR and further drug development of the HT2B
selective antagonist, we used the MembEnsemb (later version of the MembStruck)
techniques to predict the 3D structure for the hHT2BR and hHT2CR and we used the
GenMSCDock (later version of the MSCDock)3 techniques to predict the binding site for
agonists (HT, SNF, RNF, desmethylNF, ethylNF), and antagonists (SB-206533 derivatives,
PRX-08066), including some highly selective 5-HT2B antagonists known from the
literature.
We report the predicted binding site and energies for five known agonists and nine
antagonists (Fig. 1, Fig. 2, and Table 1), finding relative affinities that correlate well with
experiment. We also report the key residues in the binding site that determine the selectivity
of highly selective 5-HT2B ligands binding to hHT2BR over hHT2AR/hHT2CR. The
different binding preference of agonists vs antagonists were studied through ensemble
docking. Our molecular dynamics (MD) studies in explicit lipids and water show ligand-
induced conformational changes, with the salt bridges in D(E)RY motif maintained in
antagonist dynamics but broken in agonist dynamics. We observed that binding of the
agonist induce water to flow into the NPxxY region which seems to be important in
allowing the conformational transitions upon activation.
RESULTS
1. Structure predictions of the 5-HT2B structure
Over the last two years, structures for two family human G protein-coupled receptors
(GPCRs) have been reported: human β2 adrenergic (hβ2AR)4–6 and human A2A adenosine
receptors (hAA2AR)7. In addition the structures for turkey β1 (tβ1AR),8 bovine rhodopsin
(bRho),9–13 and opsin14, 15 are available. Unfortunately, these structures include an inverse
agonist or antagonist, providing little information about the structures involved upon
activation by agonist binding.
The predicted seven TM regions for the three 5-HT2 receptors are shown in Fig. S1 in
Supporting Information. Because the experimental structures for some GPCRs show α-
helical extensions well beyond the surface of the membrane, we used a standard secondary
structure prediction (PSIPRED)16 method to predict these extensions for the 5-HT2
receptors. These extensions lead to an additional 7 residues (EQRASKV) at the cytoplasmic
N-terminus of TM6, as shown by underlines in Fig. S1. This includes the (D/E)RY motif
expected to be important either in stabilizing the inactive state or facilitating activation.
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1.1 TM predictions—The seven TM regions of the 5-HT2B receptor were first predicted
by hydropathicity analysis and information from sequence alignments. At ExPaSy home
page, a blast search on the query sequence (P41595, 5HT2B_HUMAN, 481 amino acids
(a.a.) sequences) with NCBI BlastP 2.2.15 from UniProtKB Swiss-Prot DB (options;
mammalian and no fragment) was performed. After multiple sequence alignment using the
clustalW program, v.1.8.3, the TM regions were predicted using three ways depending on
the input sequences; i) a variety of protein sequences from other family, ii) only 5-HT
family receptors, iii) individual TM sequences. The following is the result of each case.
i. TM prediction 1 using a variety of protein sequences: A variety of 253 protein
sequences from other GPCRs with sequence identities from 18 to 98% was first
generated. The 253 sequences included HT (hydroxytryptammine, serotonin
receptor), DR (dopamine receptor), AD (adrenergic receptor), HR (Histamine),
TAA (Trace amine-associated receptor), CCKAR (Cholecystokinin receptor),
GAST (Gastrin precursor), ACM (Muscarinic acetylcholine receptor), AA
(Adenosine receptor), NMUR2 (Neuromedin-U receptor 2) family receptors,
displaying gaps in TMs 1, 5, and 7. The second filtering generated total 118
sequences with identities from 18% to 98%, excluding HRH1 receptor and filtering
the species of human, rat and mouse to avoid the redundancy of gene sequence.
Total 118 sequences revealed gaps in TMs 1, 2, and 4. Three passes were run,
eliminating gap sequences until the appropriate TM regions and hydrophobic
centers were yielded. Removing the sequences of AD and TAA receptors, 91
sequences with 18 to 98% identity showed gaps in only TM2. Further removing the
sequences which showed the bulge in TM2 (DRD1R, DRD5R, HT4R) and
increasing the population of high or middle sequence identity, final 46 sequences
with 20 to 98% identity successfully generated 7 TM regions without any gaps in
TM regions.
ii. TM prediction 2 using the 5-HT receptor family: After filtering out the non-5-HT
receptor family from 46 sequences of TM prediction 1, total 29 sequences were
used for predicting 7 TM regions. The 7 TM regions and the hydrophobic centers
without any gaps were generated similarly.
iii. TM prediction 3 using an individual TM as a query sequence and a variety of
protein sequences from the other family as an input: Each TM regions were decided
using an individual TM query sequence adding 4 to 6 a.a. at the end of TM region
from the result of TM prediction 1 (40 a.a. for TM1, 47 a.a for TM2, 40 a.a. for
TMs 3 and 4, 41 a.a. for TM5, 42 a.a. for TM6, and 43 a.a. for TM7). In each case
except TMs 4 and 6, the sequences with the gaps were eliminated until the
appropriate TM regions and hydrophobic centers were yielded.
The comparison of all three TM predictions in Table S1 in Supporting Information displayed
that predicted TM 7 region was exactly same among three methods. The other TM regions
had a good agreement within 1 up to 4 residue differences. The hydrophobic centers also
showed within 1 or 2 a.a. deviation. However, the hydrophobic center of TM2 from TM
prediction 2 revealed 10 residue differences.
To avoid the Pro problem in Helical Dynamics, four residues LVLC before Pro were added
to the N-terminal of TM3. To study the ionic lock in DRY motif, two residues RA were
considered as a helix part of the beginning of TM4. In addition, the 5-HT2B receptor was
regenerated including EQRASKV at the cytoplasmic part of TM6. These helix extensions of
TMs 3, 4, and 6 agreed well with the secondary structure prediction using PSIPRED
server16 which was predicted those extensions as a helix part, as shown in Fig. S2. The final
TM region of the 5-HT2B receptor was shown in Fig. S3.
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1.2 The hydrophobic centers (Peak vs Area methods)—Initially we chose the
center of each TM region from a combination of the middle of the predicted TM region
modified by any maximum in the hydrophobicity17, 18 over this region. The peak method
finds the stable window which does not deviate 5 or more from the value at window size 20
and average those stable values. We also use the area method, the centroid of the
hydrophobicity area above the baseline, as an alternative method. The area method bisects
the area in the hydrophobic curve using Metlab program.
In Table S2 in Supporting Information, hydrophobic centers of the 5-HT2B receptor were
compared in TM prediction 1 to 3. In TM prediction 1, the hydrophobic center of TMs 2, 3,
and 7 revealed around 5, 2, and 2 residue difference between two methods, respectively. In
TM prediction 3, only TM2 displayed 3.5 residue difference and other TMs revealed similar
centers.
Since the hydrophobic centers are important in the translational orientation of each
individual helix, four structures of two different hydrophobic centers (the peak and the area
methods) and energy scale (Eisenberg vs Octanol) from Cartesian-Neutral dynamics were
generated for next step of PDB template generation and compared the protein packings.
1.3 PDB templates—For the generation of the 5-HT2B structure, three PDB templates,
frog rhodopsin (fRho),19 mouse Mas-related gene (Mrg) C11 (mMrgC11),20 and human
CCR1 (hCCR1) Chemokine receptor,21 were used. Each template displayed different
sequence identity of whole sequence with the 5-HT2B receptor; 14% (17% in TM) for fRho,
13% (18% in TM) for mMrgC11, 17% (21% in TM) for hCCR121. Compared to the
structure generated by the fRho template, the RMSD of the 5-HT2B structure generated by
mMrgC11 and hCCR1 receptor templates showed 3.44 and 3.98 Å, respectively, as shown
in Fig. S4 in Supporting Information. Major structural deviations are shown at the tilting of
upper TM5 in mMrgC11and the tilting of lower TM2 and upper TM4 in hCCR1. Since the
structure from mMrgC11 receptor displayed the similar structure with fRho, two structures
of the 5-HT2B receptor from fRho and hCCR1 template were used for further steps.
Two minimized structures of the 5-HT2B receptors generated by two different templates,
fRho and hCCR1 receptors were compared. The MPSim energy suggested the 5-HT2B
receptor from fRho template displayed lower energy with ~60 kcal/mol than that from
hCCR1 template at the same RMS force, 0.09 because of better van der Waals (vdW)
interaction. Thus, the 5-HT2B receptor from fRho template was selected for the further
study.
1.4 Secondary structure extension at TM6—To study the interaction of ionic locks in
DRY motif, additional combinatorial set with the extension of TM6 as an α-helix structure
was regenerated; −60° for TM1, 60° for TM2, 0° for TM3, 60° for TM4, −30 and −60° for
TM5, 30 and 60° for TM6, 0 and 30° for TM7. Finally, Best 10 structures from 152
combinatorial sets were minimized and compared by Scream total energy (Etot = Tot-fm +
Tot-ScSc), total energy of charged (MinEtot,) and neutral system (NeuEtot). Previous best
structure (−60, −60, 0, 60, −30, 30, −30°) from new generated TM6 extended structure
showed all winners.
To select which hydrophobic centers and energy scale to use, four structures of each
receptor were analyzed for putative binding sites and H-bonding networks. When compared
H-bonding networks of TMs 1-2-7 (N1.50, D2.50, N7.49) and TMs 2-3-4 (S2.45, H3.42,
W4.50), the structure of the peak method and Octanol scale displayed the best H-bonding
networks which are conserved in family A GPCRs, while the structure of the area method
could not mimic the classical H-bonding networks of TMs 2-3-4 and revealed unrealistic
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kinks at TM7. In addition, when compared the orientation of the conserved residue in each
TM, rotation by Octanol scale gave better orientation than rotation by Eisenberg scale
except TM2. Thus, the structure of the peak method and Octanol scale was selected for
further steps.
1.5 Helix scan—Hydrophobicity penalty decided the appropriate rotational range of
hydrophobic scales within ~2 kcal/mol energy difference for further interhelical energy scan
in Fig. S5 in Supporting Information. For example, in TM2, 0 to 90°, −90 to −150° in blue
line were selected. Other TMs were also chosen by Penalty E; 90 to −180 degree for TM1, 0
to −120°/90 to 150° for TM3, all angles for TM4, 30 to −150° for TM5, 0 to −120° for
TM6, −30 to 30°/180° for TM7. Interhelical energy scans within 2 kcal/mol hydrophobicity
penalty energy difference using SCREAM22 yielded the optimal angles of rotation for each
helix.
Hydrophobicity penalty and interhelical energy scans in Fig. S6 in Supporting Information
yielded the optimal angles of rotation for each helix to produce a combinatorial set of
hundreds of conformations. Three passes of combinations were produced, yielding 144
different conformations, one of which is to be selected as the best packing structure. For the
first combinatorial set (total: 128), two energetically favorable angles for each helix were
selected by Scream E1; 30 and −60 for TM1, 0 and −150 for TM2, 0 and 150 for TM3, 30
and 60 for TM4, 30 and −30 for TM5, 30 and 120 for TM6, 30 and 180 for TM7 as shown
in red ball. For the second combinatorial set, 8 additional structures were generated; −60 for
TM1, −30 for TM2, 0 and −30 for TM3, 30 and 60 for TM4, −30 for TM5, 30 for TM6, 0
and 30 for TM7. For the third combinatorial set, 8 additional structures were generated; −60
for TM1, −30 for TM2, 0 and −30 for TM3, 30 and 60 for TM4, −30 for TM5, 30 for TM6,
0 and 30 for TM7.
Total 144 combinatorial sets were sorted by polar screamed E, E1 (Totfm + Totscsc −Vscsc
− Cfsc − Intern), E2 (Totscsc − Vscsc), and E3 (Totfm − Vtot − Intern). Since E3 best
showed the best packing structure, −60, 60, 0, 60, −30, 30, −30 angles for each TM helix
were chosen. However, E1 and E2 best structure (30, −150, 0, −60, −30, 120, 30°) didn’t
show the classical H-bonding network of TMs 1-2-7, because the orientation of the side
chains of D2.50 and N1.50 directed toward the membrane.
Finally, the hydrophobicity penalty and interhelical energy scans are to be re-examined for
the best packing structure. Since two more energetically favorable angles for 120° in TM1
and 90° in TM2 were shown in the second MembScream, 4 more combinatorial sets were
generated and reordered by E1 + P*9, E2 + P*9, and E3 + P*9. Current all 0 angles for all
TM helixes were detected as an energetically favorable helix orientation. In addition, the
final best structure revealed better H-bonding networks of TMs 1-2-7 and TMs 2-3-4 as well
as ligand binding compared with the beginning structure before MembScream.
Fig. S6 in Supporting Information shows the energetic for the most stable 10 predicted
conformations selected from a sequence of optimizations.
For self-consistency, the best packing structure from MembEnsemb was re-examined using
the recently developed BiHelix method. BiHelix determines the optimum configuration by
sampling all combinations of the rotations of each of the 7 helices through 30 ° rotations,
leadings to (12)7 ~ 35 million conformations, for each of which the side chains are
optimized using SCREAM.21 To make this practical we evaluate ESCREAM for each of the
144 helix pair combinations for each of the 12 nearest pairs of helices (1-2, 2-4, 4-5, 5-6,
6-7, 7-1, 3-1, 3-2, 3-4, 3-5, 3-6, 3-7) to estimate the total energy for the full 35 million 7-
helix bundle conformational combinations. We use the CombiHelix step to build the 1,000
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combinations with the lowest estimated energy into explicit 7-helix bundles and calculate
the total energy after optimizing the side chains (SCREAM). Then we select the best 100
using ESCREAM and minimize for ~10 steps using the DREIDING 3 force field (FF)23. The
best 20 of these bundles is then immersed in an implicit membrane using a Poisson-
Boltzmann model with separate dielectric constants for the middle of the membrane, the
surface regions of the membrane and the exterior. This provides membrane solvation effects
that disfavor helix rotations exposing charged residues to inner part of the lipid bilayer.
1.6 The 5HT2C structure—To study the subtype selectivity, the hHT2CR structure was
mutated from the final best structure of hHT2B receptor. All mutated side chains were
reassigned by SCREAM method. The lowest neutral energy angles for the 5-HT2B receptors
were 15, 15, 0, −15, 15, 15, 0 for TM 1 to 7, while the lowest energy angles for the 5-HT2C
receptors were 0, 30, 0, −30, 0, 0, −30 for TM 1 to 7. The preferred angles for each TM
between two subtypes revealed ± 15 angle differences among the subtypes. TM7 showed
30° angle deviation, while 0 is the best in TM3 in both cases.
Summarizing, we concluded that the best structure is the one with the lowest total energy
(MPSim E) based on the hHT2BR (fRho template) using the peak hydrophobic center, the
Eisenberg hydrophobicity scale, and the Cartesian-Neutral dynamics. The predicted best
packing structure has the conformation {−60, 60, 0, 60, −60, 60, 0 °} with respect to the
fRho template.
1.7 Bihelix/CombiHelix result—To validate the predicted structure, Bihelix/CombiHelix
were performed for the best packing structure. The Table S3 in Supporting Information
shows the top 10 structures out of ~35 million from the BiHelix analysis. The best packing
structures from MembEnsemb (All 0 ° angles correspond to the angles of −60, 60, 0, 60,
−60, 60, 0 ° from MembEnsemb) ranks as number 2 by total E. The best one differs by a
−30° rotation of TM4. The top 10 from the 1000 structures of CombiHelix built explicitly
are shown in Table 2. We find that the all 0 ° structure leads to the best total E. We also find
low lying structures with ± 30° variations of TMs 4, 6, and 7.
This final predicted three-dimensional structure of the hHT2BR possesses the H-bonding
network found in the other known class A GPCR structures.
In the middle of TM, D2.50 forms a hydrogen bond (HB) to N1.50.
H3.42 forms a HB with S2.45 and with W4.50.
In the expected ligand binding site of the apo-protein, we find a HB between D135 and
Y370 (both are highly conserved within biogenic amine receptors). We find that the
predicted hHT2BR structure leads to an ionic lock involving the (D/E)RY motif. Thus
we find two salt-bridges between D152 (3.49) and R169 (4.39) and between R153
(3.50) and E253 (6.30) on the cytoplasmic end. These ionic bonds are consistent with
two experiments;
The E6.30R mutation shows a highly constitutively active receptor with enhanced
affinity for agonist through disruption of ionic interaction.24
R4.39E displays constitutively active arrestin mutant, stabilizing the agonist-high
affinity state.25
2. Predicted structures for hHT2BR ligands
First, we docked the rigid SB-206533 1, 5-methyl-1-3,5-dihydro-2H-pyrrolo[2,3-f]indole-1-
carboxylic acid pyridine-3-ylamide, (Fig. 1). This has >100 fold selectivity in binding to 5-
HT2B over 5-HT2A and other receptors, which was based on the first selective pyridyl urea
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5-HT2C/2B antagonist, SB-200646A.26 Then we studied another conformational restricted
analogue 2 (1-methyl-1-1,6,7,8-tetrahydro-pyrrolo[2,3-g]quinoline-5-carboxylic acid
pyridine-3-ylamide) through the introduction of a six membered ring which is clearly
detrimental to 5-HT2C receptor affinity (pA2, 5-HT2B: 7.27 vs pKi, 5-HT2C: 5.39).27.
In addition, we predicted the binding site of PRX-08066 3 (Fig. 1) from EPIX
pharmaceutical company known to be a highly potent (Ki ~ 1.7 nM) and selective 5-HT2B
antagonist (Ki > 100 fold for more than 55 receptors tested).28 It (pKi, hHT2B: 30 nM) has
good bioavailability, preclinical safety profile, and a low order of acute toxicity, which is
under Phase II clinical trials for the treatment of pulmonary hypertension and hypoxia-
induced pulmonary hypertension syndromes.
Receptor modeling studies of the 5-HT2C receptor suggested that the observed selectivity of
5-HT2B/2C receptors in SB-206533 1 was expected from two valines, V212 and V608, of
which the corresponding amino acids were Leu in the 5-HT2A sequence, thus constricting
the pocket.29 However, little is known about the selectivity between 5-HT2B and 2C
receptors.
Here, we report the predicted binding site and energies for five known agonists and nine
antagonists (Fig. 1, Fig. 2, and Table 1), finding relative affinities that correlate well with
experiment. We also report the key residues in the binding site which determines the
selectivity of the hHT2BR over the 5-HT2A/2C receptor through the docking study of
highly selective 5-HT2B ligands.
2.1 Selective hHT2BR agonist 4 (SNF)—Site directed mutagenesis, binding studies,
ligand docking, and MD simulations suggest that terminal methyl groups of V103 in the
hHT2BR form stabilizing vdW interactions with the α-methyl group of SNF.1 The role of
V103 in SNF binding to 5-HT2 receptors was subtype selective. Our predicted structure
agrees with the experimental data in the reported literature.1 The protonated amine nitrogen
of SNF 4 shows an ionic interaction at conserved D135 in the biogenic amine receptor. An
additional vdW interaction between the α-methyl group carbon of SNF and the terminal γ-
methyl carbon of V103 stabilizes the complex with 3.79 Å distances, as shown in Fig. 3.
To validate our model, we studied the stereo selectivity using the other isomer. We find that
the (R)-enantiomer of norfenfluramine binds in the same orientation as SNF, with a major
anchoring interaction at D135. However, the α-methyl group of RNF is away from the
terminal γ-methyl carbon of V103 by 5.96 Å, missing favorable vdW interactions in Fig. 3.
We find that desmethylNF also has no vdW interaction at V103 because of the absence of
the methyl group. We find that ethylNF has unfavorable vdW interaction with the β-methyl
carbon of the terminal ethyl carbon. The V103L mutation has little effect on 5-HT affinity,
while the V103L mutation markedly and uniquely affects SNF binding to hHT2BRs.1
Compared with SNF (−25.87 kcal/mol in neutral cavity E), the binding E indicates that
RNF, DesMeNF, and EthylNF have a higher binding by 0.32, 0.45, 2.92 kcal/mol (see Table
S2). Therefore, we predict that SNF is the strongest binder at 5-HT2BR, consistent with the
experimental binding affinities (SNF > DesmethylNF > RNF > EthylNF).1
2.2 Selective hHT2BR antagonist 1 (SB-206553) and 2—We docked the
nonselective 5-HT2B/2C receptor antagonist, SB-206533 1, to both of the hHT2BR and
hHT2CR, as shown in Fig. S7A and 7B in Supporting Information. Common HB
interactions were found between the ureido-CO group and the Ser-OH side chain at
conserved S139 among 5-HT2 family receptor. Comparing the cavity analyses, similar non-
bonding E is shown at the hHT2BR and at the 5-HT2C receptor. Additional hydrophobic
interactions stabilize the complex at conserved residues, V136, F274 (2B)/F272 (2C), and
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F299/F298. The N-methyl of the cyclopenta-indole ring interacts with the subtype variable
residues, L132, I186, and V190 in the hHT2BRs with nonbond energies of −2.48, −0.10,
and −0.76 kcal/mol, respectively. The corresponding amino acids at the 5-HT2C receptors,
I132, V186, and I190, also have favorable interaction with nonbond energies. Thus,
SB-206533 1 at the 5-HT2B and 2C receptor shows similar total cavity E, −42.48 and
−42.28 kcal/mol, respectively. In addition, subtype-selective residues also reveal similar
interaction in Table S4 in Supporting Information.
We predict that the 5-HT2B selective antagonist 2 in Fig. S7C/7D in Supporting
Information. The ureido-CO group has a major HB interaction with Ser-OH at conserved
S139, stabilizing hydrophobic interactions with surrounding hydrophobic residues at
conserved residues, V136, F274, and F299. We predict that the major reason for reduced
interaction at the HT2C receptor is bad contacts at I132, which has unfavorable vdw
interaction (+6.24 kcal/mol), compared with the favorable vdW interaction at the hHT2BR
(−2.32 kcal/mol), making binding at the 5-HT2C receptor unfavorable by +8.46 kcal/mol.
Other subtype selective residues, V190/I190 in 2C, L281/S279 in 2C, showed similar
binding energetic. Consistent with experiment, we find favorable interaction at HT2BR
(−47.53 kcal/mol), while binding to the HT2CR is +11.47 kcal/mol less favorable (Table
S4). Fig. 4 superimposes 1 and 2, showing that the N-methyl of the cyclohexa-indole ring of
2 is closer to the upper TM3 leading to unfavorable interactions with the bulkier Ile side
chain in 5-HT2CR (I132), while the methyl of the cyclopenta-indole ring in 1 points toward
the upper TM 4. In addition, the cyclohexa-indole ring is bordered by hydrophobic L281 in
hHT2BR, while it is near the hydrophilic residue S279 in the 5-HT2CR.
Further SAR studies were used to validate the current binding mode.30 Based on the
experimental SAR in Table 1, the lipophilic group at R5 position and the electron-
withdrawing group at the 6 position were optimized. Our predicted energies correlate well
with the experimental binding affinity at 5-HT2BR/2CR, with correlation coefficient (r2
value) between experimental binding affinities (Pki) and the calculated cavity E of 0.83 and
0.91 at the human 5-HT2B and 2C receptors, respectively. We find that the R5 lipophilic
substituent is bordered by an aliphatic environments (V3.33, L3.29, I4.56, V4.60, M5.39,
A5.46), while R6 has electron-withdrawing group is in the proximity of L3.29, S5.46 and
N6.55 (Fig. 2).
2.3 Highly selective hHT2BR antagonist, 3 (PRX-08066)—To obtain a better
understanding of the molecular basis of the subtype selectivity of highly potent and selective
hHT2BR antagonist 3, we dock this ligand (see Fig. 5 and Fig. S8). We find that D135/D134
in TM3 (2B/2C) have a common salt-bridge with a protonated amine in pyridine ring (−7.52
for 2B vs −7.70 for 2C). We find that the N atom of the thienopyrimidine ring makes an
additional HB at with the side chain NH of N344/N311 in TM6. We find that several
hydrophobic residues stabilized the complex through vdW interaction; the cyano group with
V103/V102, the thienopyrimidine ring with F274/F272, L132/I132, and V190/I190 (Table
S5 in Supporting Information). We predict that the binding is 24.27 kcal/mol more favorable
interaction at 5HT2BR compared to 5HT2CR supports, consistent with experiment.
To learn more about subtype selectivity, we examined the effect of mutations in the 5-HT2
receptors on binding of antagonist 3 based on the multiple alignment of 11 serotonin
receptors in Fig. S9 in Supporting Information. Here we examined mutations at L132, L347,
V103, M218, V190, S372, in the TM regions and K211, T210, E212 in extracellular loop
(EL) 2. Each residue was mutated into all 20 amino acids and the side chains reoptimized.
Then we match the ligand to the new binding site and minimized the E for each mutant. We
found that all mutations decreased the affinity of 3. Thus the mutant L132I to mimic 5-
HT2A/2C receptors revealed major decreased interactions by 6.8 kcal/mol compared with
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the wild type (see Fig. S10 Supporting Information), supporting the direct role of this
residue in the selectivity of 3. Other mutants show that L347A (2A) or S (2C), L347A (2A),
V103L (2A), M218V (2A/2C), V190I (2A/2C), and S372C (2C) also lead to small
decreased interactions by 2.1, 3.4, 4.2, 0.3, 0.7, and 0.5 kcal/mol, respectively. Mutations in
EL2, K211D (2A/2C), T210A (2A) or N (2C), E212D (2A) or F (2C) have a negative effect,
decreasing binding by 1.1, 0.8, 0.8, 0.8 and 0.0 kcal/mol, but little contribution to the
selectivity of 3). These results show a direct affect of mutations on affinity and selectivity.
Our results are consistent with reported mutational studies. Mutations at V103 and A225
show that they play a role in the 2B/2C selectivity.31 We propose additional mutation
studies at residues, L132, V190, and L347, to test our predictions that they are involved in 5-
HT2B/2C selectivity. For the 5-HT2B selective ligands 2 and 3 studied, we found that the
side chain at L132 directly determines relative ligand selectivity.
2.4 Docking of endogenous agonist, HT and selective antagonist, 2 to low
lying structures of 5-HT2B—To determine whether other low lying structures of HT2B
might play a role in activation, we docked the endogenous agonist, 5-HT, and 5-HT2B
selective antagonist 2 into the five lowest-lying packing structures from the CombiHelix
predictions in Table 2.
We find that agonist HT binds best to bind to the all 0 structures, but it binds unfavorably to
the structure with TM6 rotated by 30° (clock-wise from the extracellular view). This agonist
binding preference correlates with experimental data; suggesting that binding agonist causes
TM6 to rotates anti-clockwise.32.
However, we find that antagonist 2 prefers a slightly different conformation, with TM7
rotated by − 30°, as shown in Table S6 in Supporting Information.
3. Dynamics
To study the effect of membrane and water on the structures of the ligand-GPCR complex,
we inserted the predicted protein-ligand complexes into a periodic infinite membrane fully
solvated with water and carried out 10 ns of MD at 300K.
3.1 Apo-hHT2BR dynamics—After 10 ns of MD, the major change in the structure
observed is a ~ −20° rotation of TM 4. We find that TM6 exhibits large variations with
fluctuations +/− 28°. However, the effective change of P6.50 position in TM6 compared to
the starting structure is ~ −10° rotation.
The following stable HB networks among TMs in the simulation were shown in Apo-
hHT2BR dynamics.
N72 (1.50) and D100 (2.50); the average heteroatom distance HB of 3.5 Å,
S142 (3.39) and S307 (7.46); the average heteroatom distance of 3.2 Å,
S142 (3.39) and N310 (7.49); the average heteroatom distance of 3.3 Å.
In the binding site, we find that three HBs are stable;
D135 (3.32) and Y304 (7.43); the average heteroatom distance of 3.7 Å,
D135 (3.32) and W131 (3.28); the average heteroatom distance of 3.6 Å.
S139 (3.36) and W271 (6.48); the average heteroatom distance of 2.9 Å.
In addition new HBs are formed in the cytoplasmic end;
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S150 (3.47) and Y314 (7.53) in the NPxxY region; the heteroatom distance changes
from 10.1 Å to 3.8 Å.
D152 (3.49) and R153 (3.28) in the D(E)RY region; the heteroatom distance changes
from 11.9 Å to 3.8 Å.
3.2 Agonist (5-HT)-hHT2BR dynamics—After 10 ns of MD, the major change in the
agonist (5-HT) bound structure is at TM 6 which rotates by ~ −80° (anti-clockwise), which
is consistent with experiment.31 TM 6 also shows the largest fluctuations in the average η
angle by +/− 55°. The change in η difference is 7 ° for N1.50 in TM1, −34 ° for D2.50 in
TM2, 6 for D3.32 in TM3, 25 ° for W4.50 in TM4, −5 ° for P5.50 in TM5, −113 ° for P6.50
in TM6, and 15 ° for P7.50 in TM7.
Interestingly, we found that all of the salt-bridges in EL (E82-K84, E82-K385, D152-R169,
R153-E253, E319-R321) and IL (K193-D216, K211-D351, R213-D351) in the agonist
(HT2)-hHTBR are unstable, breaking by 8ns.
The following stable HB networks among TMs in the simulation were shown in Agonist (5-
HT)-hHT2BR dynamics.
1. N72 (1.50) and D100 (2.50); the average heteroatom distance of 3.9 Å.
2. S95 (2.45) and H145 (3.42); the average heteroatom distance of 3.5 Å.
3. H145 (3.42) and W180 (4.50); the average heteroatom distance of 3.0 Å.
In the binding site, major anchoring interactions were stable;
1. D135 (3.32) and the protonated nitrogen; the average heteroatom distance of 3.5 Å,
2. S139 (3.36) and the OH group; the average heteroatom distance of 4.1 Å,
3. S222 (5.43) and the NH group; the average heteroatom distance of 3.4 Å.
3.3 Antagonist (2)-hHT2BR simulations—After 10 ns of MD, the major changes in
the antagonist (2) bound structure a ~120° rotation (clockwise) at TMs 6, unlike the agonist
(5-HT)-hHT2BR. However, the fluctuation of TM6 is +/−20 °. The average η difference of
N1.50, D2.50, D3.32, W4.50, P5.50, P6.50, and P7.50 are 16, −27, −24, 15, 6, −20, and −1°
angle. Compare to agonist (5-HT)-hHT2BR, the rotations of TMs 3, 5, and 7 are opposite.
Although TM6 showed the same rotation, the change is much small (−20 °) in the antagonist
(2)-hHT2BR simulations, compared to the agonist (HT)-hHT2BR model (−113°).
Major interactions in the binding site were stable; S139 and the ureido-CO; the average
heteroatom distance of 3.0 Å. The ureido-CO group also revealed new weak H-bonding with
4.1 Å average heteroatom distance of H-bonds at W337 which also interacted with S139,
resulting in final 2.9 Å heteroatom distance of H-bonds after 10 ns.
Unlike the agonist-bound structure, we found that two salt-bridges between K211-D351 and
between K193 and D216 in EL relatively stable during the MD. Thus all three salt-bridges
in IL (D152-R169, R153-E319, and E319-R321) are maintained.
With antagonist (2)-hHT2BR, we observed much less motion of the ligand in the binding
site, and there were no big differences in the average backbone root mean square deviation
(BRMSD) of TM helices (~ 2.0 Å for all three cases). After 10 ns the RMS change in
antagonist 2 was 1.0 Å (the average RMSD of 0.6 Å), while the RMS change for agonist HT
was 3.9 Å (the average RMSD of 3.1 Å). Thus binding of agonist induces motion in the
active site while binding of antagonist leads to a more rigid structure. This increased rigidity
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of the antagonist (2)-hHT2BR system may block the conformational change for constitutive
activation.
The following stable HB networks among TMs in the simulation were shown in Antagonist
(2)-hHT2BR simulations.
N72 (1.50) and D100 (2.50); the average heteroatom distance of 2.8 Å
S95 (2.45) and H145 (3.42); the average heteroatom distance of 4.0 Å.
D135 (3.32) and Y370 (7.43); the average heteroatom distance of 3.1 Å
S139 (3.36) and W271 (6.48); the average heteroatom distance of 2.9 Å.
3.4 Water channel from the binding site into the NPxxY motif—We observed
water entering the conserved N1.50-D2.50-N7.49 area (NPxxY region) during the MD for
all three cases. However just two waters moved into this region for the apo-hHT2BR,
compared to 6 for the antagonist complex, and 14 for the agonist complex. We found a
common water path in the ligand-bound system as shown in Fig. 6. Thus binding of agonist
promotes migration of water inside the protein, which facilitates the conformational change
upon activation compared with the antagonist.
In the apo-hHT2BR-membrane complex, two water in the NPxxY region (water within 5 Å
of N1.50, D2.50, and N7.49 in VMD program). Thus by 1.7 ns, two water molecules in the
NPxxY region were observed in the water layer, passing through the D(E)RY motif which
was important for family A GPCR activation, as shown in Fig. 6.
Water in the proximity of D135 (3.32) which is the major anchoring point with the
protonated nitrogen passed into S307 (7.46), S142 (3.39) into NPxxY region. This
phenomenon suggests that ligand binding in the binding site might regulate the
conformational change at the NPxxY region through water.
In the antagonist (2)-bound hHT2BR, water in the proximity of D135 or Y304 in the binding
site enters into the NPxxY region, forming HBs with D100, N310, S142 and S307.
In contrast the dynamics of agonist (5-HT)-bound hHT2BR shows water in the proximity of
N278 or Y304 in the binding site penetrate into the NPxxY region, forming HBs with D100,
S142 and S307. More water in the NPxxY region are floating around in the water pocket
through alternative HBs with neighboring hydrophilic residues, N72, D100, S142, S307 and
N310. In particular, W271 which is involved in the water channel are thought to control the
beginning of activation) as a rotamer switch. One water near R153 also can go into N72.
This means the possibility of the cross-talk between the D(E)RY and the NPxxY regions.
The corresponding amino acids of S142 (3.39) and S307 (7.46) in bRho are the hydrophobic
residues of Ala. Unlike bRho, hHT2BR displays a constitutive basal activity.33 The
hHT2BR seems to provide more flexibility of the protein through the alternative H-bond
interactions at two additional hydrophilic regions, S3.39 and S7.46, in the water channel.
These additional hydrophilic residues in the water channel extending from the binding site to
the NPxxY region correlate with the higher basal activity or protein instability compared to
bRho.
Explicit water mediates the H-bond between S222 and the tryptophan NH-group of agonist
(5-HT) after 1ns MD. After 9 ns, preserved interactions in the binding site between
protonated nitrogen and D135 convert into water-mediated interactions.
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3.5 Ionic-lock stability in the D(E)RY motif—For the apo-protein structure of
hHT2BR the ionic locks between R153 and E253 and between D152 and R169 in the
D(E)RY region constrain the motions of helix 6 relative to 3.
1. In apo-protein dynamics, the interaction between TMs 3 and 4 is stable, while the
other salt-bridge between TMs 3 and 6 is not stable, as shown in Fig. 7. The first
break between R153 and E253 occurred at around 2 ns but the H-bond was
reformed later. However after 6 ns, the distance between two hetero atoms of the
counter charge increases with the final heteroatom distance of 9.1 Å, while the
other final heteroatom distance is 2.6 Å.
2. In agonist (5-HT)-hHT2BR, both of the salt bridges are broken after 6 ns and 8 ns.
The interaction between R153 and E253 is first destabilized. Final distances
between R153 and E253 and between D152 and R169 were 13.2 and 9.8 Å,
respectively. Supporting this, TMs 4 and 6 resulted in the high BRMSD in Fig. 7.
3. In the antagonist (2)-bound hHT2BR simulation, both interactions were stabilized.
Final distances between R153 and E253 and between D152 and R169 were 3.1 and
2.5 Å, respectively.
4. These observation support the idea that the D(E)RY-motif plays an important role
in protein activation.34 Thus, the motions observed with respect to helix 4 and 6
provide a strong indication that such changes are involved in protein activation.
DISCUSSION AND CONCLUSIONS
The dynamics for the agonist-hHT2BR structure leading to substantial migration of water
into the NPxxY region and the breaking of the ionic lock suggest that binding of the agonist
might be able to cause activation of the GPCR. The second alternative is that there might be
two or more stable states of the receptor (inactive state R and active state R* with the full
agonists binding to R*, while inverse agonists binding to and stabilizing R). Indeed there is a
growing body of experimental evidence for the existence of multiple conformational
states.35 Our results indicate that several distinct conformations can bind to the agonist and
the antagonist, supporting the idea of multiple conformations.
Our ensemble docking result with several lower-lying packing structures of hHT2BR from
BiHelix/CombiHelix method revealed the different binding preference between an
endogenous agonist (5-HT) and a HT2B selective antagonist 2. The antagonist 2 preferred to
bind to the structures for which TM7 was rotated by −30 °. However, the agonist 5-HT
revealed weak interactions in the structures for which TM6 was rotated by 30 ° in the clock-
wise rotation from the extracellular view. The predicted agonist binding preference is
consistent with the experimental data, the anti-clockwise rotation of TM 6 from the
extracellular view.32.
Examination of the MD trajectory indicates that antagonist-hHT2BR simulations differ
substantially from the dynamics of the apo-hHT2BR and of the agonist-hHT2BR systems.
Both of the two salt-bridges in the D(E)RY regions of the antagonist (2)-bound hHT2BR
simulation were relatively stable during the simulation, while both interactions were broken
in agonist (5-HT)-hHT2BR after 6 ns and 8 ns, sequentially. Apo-dynamics display the
intermediate stability of these interactions. The interaction of TMs 3 and 4 is stable, but the
other salt-bridge between TMs 3 and 6 is not stable, as summarized in Fig. 7.
In addition, the comparison of the dynamics of agonist and antagonist-bound HT2BRs
shows the high RMSD of agonist in the binding site. The more flexible agonist in the
binding site allows more water inside the protein and forms a water channel from the
binding site to the loosely packed NPxxY region. This region is believed to be important in
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allowing conformational transitions as there will be fewer steric restraints to side chain
packing. Floating water in the NPxxY region is thought to act like a buffer to reduce a steric
clash or an electrostatic repulsion between the same charges when the conformational
change occurs.
As conclusions, the general agreement of the predicted structures with experimental
mutation and binding data suggests that these methods protein structure prediction are
reasonably accurate. Thus:
1. The final best structure of the hHT2BR from MembEnsemb and BiHelix leads to
the ionic lock involving (D/E)RY motif and we expected TMs 1-2-7 and TMs 2-3-4
as networks of class A GPCRs.
2. SNF as an agonist is the strongest binder at the hHT2BR among four derivatives,
consistent with their experimental binding affinity (SNF > DesmethylNF > RNF >
EthylNF).1 The cavity energies of 6 antagonists paralleled with the experimental
binding affinities at the hHT2BR and hHT2CR with the correlation coefficient (r2)
values of 0.83 and 0.91.
3. Docking complex (2) suggests a novel binding interactions for these series of diaryl
ureas, involving a hydrogen bonding interaction between the urea carbonyl oxygen
of the ligand and D139 (3.36) which is unique at 5-HT2 family receptor.
4. In the docking models of the 5-HT2B selective antagonist 2 and 3 (PRX-08066),
V103 (2.53), L132 (3.29), V190 (4.60), A225 (5.46), and L347 (6.58) lead to
subtype selectivity among the 5-HT2 family receptors.
5. The ensemble docking study with several lower-lying packing structures reveals
the different binding preference of a full agonist (5-HT) and an antagonist (2).
6. The simulations reveal that the salt bridges in D(E)RY motif are maintained in
antagonist dynamics but broken in agonist dynamics. The NPxxY region filled with
water from the ligand binding site is believed to be important in allowing the
conformational transitions upon activation.
Thus, this modeling study will help to design more potent and more selective drugs for the
hHT2BR without undesired side effects.
METHODS
1. Generation of the 5-HT2B structure using MembEnsemb program, v.4.30—
First, the three-dimensional structures of the hHT2BR based only on its primary sequence
were predicted using the MembEnsemb first principles method which was updated from the
Membstruk first principles method.36, 37 All E and force calculations used the DREIDING
FF23 for the ligand and CHARMM22 charges for the protein.38 The MembEnsemb
procedure involves the following steps.
1.1 Predict TM region: Our method for predicting the seven TM domains, PredicTM which
is developed from earlier version of TM2ndS,36 uses hydropathicity analysis combined with
information from multiple sequence alignments. We start with about 50 to 200 sequences
having sequence identities from the target structure varying uniformly from 20% to 90%.
The second step of TM2ndS is to calculate the consensus hydrophobicity for every residue
position in the alignment using the average hydrophobicity of all the amino acids in that
position over all the sequences in the multiple sequence alignment. Then, we calculate the
average hydrophobicity over a WS of residues about every residue position, using WS
ranging from 12 to 30. The average hydrophobicity value at each sequence position was
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plotted to yield the hydrophobic profile. MembStruk procedure used the Eisenberg
hydrophobicity scale, but with MembEnsemb we now use 8 different hydrophobicity scales,
1) thermodynamic hydrophobic octanol as a default, 2) the interface of octanol, 3) the
average of thermodynamic and biological hydrophobic scales, 4) biological hydrophobic
scales, 5) hydrophobicity penalty with the solvent accessible surface area developed by
Jenelle, 6) the Eisenberg hydrophobicity (the scale used by the original TMPred), 7) new
Eisenberg, and 8) interface.
1.2 Create PDB template: The initial z position of each of the 7 helices and the initial
orientation η, the initial x and y position is taken from the 7.5 Å electron density map of
fRho,19 mMRgC11,20 and hCCR121 receptors which was generated using TMPred.
In addition, the tilt (θ) of each axis from the z axis and the azimuthal orientation (φ) is taken
from this structure. This is the procedure used for previous applications of MembStruk.
However, for MembEnsemb, we are now extracting the x, y, θ, and φ from those predicted
structures of GPCRs that have been successful in predicting binding sites of known ligands
and which have been subjected to MD optimization with full membrane and solvent. We
will use one or more sets of x, y, θ. and φ from this data base as starting points for the
GPCRs being studied. After optimization, the helix is reinserted in the bundle while
preserving the major axis, which is followed by a full bundle optimization.
With the predicted TM regions for the 5-HT2B/2C receptors, the canonical helices were
generated. The helical axes are positioned according to each template, with the hydrophobic
centers on the same fitting plane.
1.3 Rotation by phobic face: The helices will be treated as canonical and have all C-alpha
carbon positions (the middle 15 residues around the hydrophobic center) projected on to the
plane that intersects the hydrophobic center and aligns the smallest moment of inertial along
the Z-axis. Then all projected C-alpha positions will be assigned their hydrophobic scalar
according to the hydrophobicity scale chosen and the program will determine the largest gap
of the helix that does not face other helices and look the largest number summing the C-
alpha numbers over that gap. The middle of the gap containing the largest sum of all C-
alphas will become the hydrophobic moment and the helix will be rotated to move this
position to 180 degrees from the center of the protein. The canonical helices for the
predicted TM segments of the 5-HT2B/2C receptors were rotated by Octanol scale for better
orientation of hydrophobic side chains facing toward the membrane.
1.4 Helix dynamics: The structures of the individual helices were optimized with E
minimization followed by 100 ps Newton-Euler inverse mass operator (Neimo) torsional
dynamics39, 40 and Cartesian dynamics with charged force field or neutral QeQ charge at
300K (NVT). This optimizes the bends and kinks in each helix due to the presence of Pro
and Gly in some TM domains. This is an important step as it is believed that the individual
helices interact with each other in the lipid bilayer during the folding process and by the start
of this interhelical interaction they would have assumed their native bent or straight helix
conformations. The presence of bent helices disallows many rotational combinations when
the helices interact with each other.
The spatial orientation of the helices, helical bends and kinks were optimized by individual
helix dynamics. The Neimo dynamics and the Cartesian-Charge dynamics produced severe
kinking and unraveling of TM 2, eliminating them as a feasible option. The Cartesian-
Neutral structure is feasible because there is little unraveling and minor kinking caused by
the presence of Pro. All prior calculations were repeated using the different hydrophobic
center of the area method.
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1.5 Rotation by hydrophobic moments: The initial orientation (η) of the helix about this
axis is determined by calculating the net hydrophobic moment of the middle one-third of the
helix (centered at the hydrophobic center) but counting only the half circle that would be
oriented toward the lipid. The calculation of the hydrophobic moments uses only the middle
15 residues around the hydrophobic center of each helix. Then these hydrophobic moments
are projected onto the plane of intersection of the hydrophobic centers. The degree of
rotation needed to point the end of hydrophobic vector 180 degrees away from the center of
the protein is used for the individual rotation of the helices. This is pointed outward from the
center of the xy positions of the seven helices. The optimized helices of the 5-HT2B
receptor from Cartesian-Neutral Dynamics were rotated by Eisenberg or Octanol scale.
1.6 MembEnsemb: To select the initial orientation of the side chains we use a Monte Carlo
procedure. Using SCREAM22 for selecting the side chain conformation considerably
improves the accuracy in comparing different rotations, and we have now eliminated the
ROTMIN step, replacing ROTSCAN with ROTSCREAM, but now the scan need only be in
increments of 30°, rather than 5°. All helices are rotated by 30° increments while reassigning
the side chain conformation by SCREAM method22. Hydrophobicity penalty and
interhelical E scan are performed to maximize the best orientation of each helix and the side
chain. For the optimization of rotational orientation of the helices, each helix is rotated
through a grid of rotational angles while reassigning the side chain conformation by
SCREAM method.
1.7 The combinatorial set using MembEnsemb: The combinatorial sets lead to an
ensemble (3 to 10) of packed bundles, each of which we may use for docking candidate
agonists and antagonists. Our working hypothesis is that GPCRs may sample 3 or 4 (or
more) packings of the helices during their dynamics as they interact with agonists,
antagonists, inverse agonists, or modulators. By determining the properties for each of the
structures in this ensemble, we expect to obtain a better understanding of which structures
might play a role in the various processes of the GPCRs (some might be more favorable for
dimers). This systematic search over a grid of rotational angles and translational distances is
important because there are likely to be substantial E barriers between some of the local
minima, which molecular dynamics simulations may not find all of them.
1.8 BiHelix and CombiHelix: The top1 of the hHT2BR from MembEnsemb was used for
running BiHelix and CombiHelix. To find a diverse ensemble of low-E packing of the TM
helices and validate the current hHT2B structure, we started with the MembEnsemb
structure and rotated independently 12 helix pairs (H1–H2, H1–H7, H2–H3, H2–H4, H2–
H7, H3–H4, H3–H5, H3–H6, H3–H7, H4–H5, H5–H6, and H6–H7) in 30° degree
increments through full a 360° (12 rotations in each helix), leading to explicit 1,728
(12×12×12) bundle configurations. For each of these theoretical 35 million TM bundle
configurations, the pair E which was indicated in details in Table S1 was calculated.
In the combinatorial set, the best 100 structures were optimized all side chains using
SCREAM, calculated the polar interhelical interaction E ignoring side chain-side chain
EvdW or all vdW E, or internal E, total interhelical interaction E and the Membrane
Solvation E (MembSolE), ordered by total E, total interhelical interaction E and MembSolE.
The CombiHelix results for best 10 are shown in Table 1. The current structure with all 0°
angles for each helix ranked as Number 1. The second low-lying structure rotated −30° anti-
clockwise way for TM4 from extracellular side. The third one showed a single rotation of
TM6 by 30°. In addition to the rotation of TM6 by 30°, the fourth one showed an additional
−30° rotation of TM7 which revealed in the fifth case. All other helices, TMs 1, 2, 3, and 5
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showed 0° structure as the lowest-lying one. Thus the best angles within best 5 are: TM1= 0,
TM2= 0, TM3= 0; TM4= 0, −30, TM5= 0, TM6= 0, 30, TM7: 0, −30.
The 0° case for each helix has the lowest E, validating that the current model is correctly
predicted through MembEnsemb procedure. We believe the other low-lying packings of the
helices may play a role in binding of agonists and/or in activation.
* The description of BiHelix energies.
The BiHelx pair energy (BiHelE) is the sum of the SCRAEM energies from all 12 pairs for
each of the 127 7-helix conformations, properly corrected for overcounting of the intra helix
interactions.
BiHelE = Sum_HiHj = Totintra-ii + Totintra-jj + Totinter-ij
where
Totintra-ii = Total intrahelical energy of Helix i in i-j pair.
Totintra-jj = Total intrahelical energy of Helix j in i-j pair.
Totinter-ij = Total interhelical energy between helices i and j.
TotinterH-ij = Interhelical hydrogen-bond energy between helices i and j.
Interhelical hydrogen-bond energy (InterHB) is the sum of all Interhelical hydrogen-bond
energies between all 12 pairs of helices.
* The description of CombiHelix energies
For each of the 7-helix conformations selected from the BiHelix analysis we built full 7-
helix bundle, scream all 7 helixes simultaneously and evaluated the energy, ScreamTot. In
addition, we evaluated the membrane solvation free energy (MembSolE, Es) using a multi-
dielectric (80|7|2|7|80) implicit membrane model of the total solvation free energy change
associated with transfer of protein from implicit bulk water.
ScreamTot = Totfm + Totscsc + Intern
i) Totfm = Intern+Vfsc+VTotfm+CHTotfm
Intern = Valence energy terms of the SCREAMed residues.
Vfsc = vdW energy between SCREAMed residue side chains and fixed residue side
chains.
VTotfm = Vfsc + vdW energy between SCREAMed residue side chains and all
backbones.
CHTotfm = Coulomb plus Hydrogen bond (HB) energy between fixed residues and
SCREAMed residue side chains.
ii) Totscsc = Vscsc+CHscsc
Vscsc = vdW energy among SCREAMed residue side chains.
CHscsc = Coulomb and HB energy among SCREAMed residue side chains.
MembSolE = Es = E1−E2+E3
E1=Polar solvation energy of the protein in a multi-dielectric (80|7|2|7|80) implicit
membrane.
E2=Polar solvation energy of the protein in implicit bulk water.
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E3=Non-polar solvation free energy change corresponding to transfer of protein from
implicit bulk water to multi-dielectric (80|7|2|7|80) implicit membrane, approximated as
γ × Lipid exposed solvent accessible surface area.
2. Generation of loops by CCBB loop builder—Loops were predicted by a new
CCBB loop builder using the CCBB Monte Carlo method developed for predicting free
energies of polymer chains combined with Restraint Generic Protein algorithm41 for
handling the constraint of terminating the loop on the adjacent TM domains.
The disulfide bond between C128 and C207 was constructed. The final structure was
optimized without any constraints. To save the simulation time in explicit membrane and
water, truncated intracellular loop (IL) 3, from A247 to V313, which was far away from the
binding site was used.
To provide initial loop structures for other low-lying packing structures, the loops of three 3
EL and 3 IL parts were connected into four other TM structure. Connection parts were
minimized with trans-amide torsional constraints and backbone freeze atoms at the α-helix
structure.
To check the quality of the model, the main chain parameters (Ramachandron plot quality
assessment, peptide bond planarity, measure of bad non-bonded interactions, alpha carbon
tetrahedral distortion, HB energies) and the side chain parameters (the standard deviation
angle of Chi-a gauche minus, Chi-1 trans, Chi-1 gauche plus, Chi-2 trans angle) used
Procheck program to reveal statistically better or reasonable results.
3. Docking Study
3.1 GenMSCDock: The putative binding sites for agonists and antagonists of the hHT2BRs
were determined using GenMSCDock. GenMSCDock was the next generation of
HierDock42and MSCDock,43 but many improvements have also been made. MSCDock was
successfully applied to mMrgC1120 and hHT2C3 receptors, as described previously. This
procedure solved the problem of allowing bulky residues and bulky ligands to accommodate
each other. The validation of GenMSCDock has been described previously.44 We docked
the antagonist, ZM241385, to the crystal structure of the hAA2AR (PDB ID: 3eml). Our
best predicted structure (best cavity energy) is 0.80 Å RMSD from the x-ray structure. The
largest deviation was at the phenoxy ring exposed toward EL 2 and 3 due to the three waters
surrounding the phenoxy ring in the X-ray complexes.
GenMSCDock sampled a complete set of configurations for each conformation of the
ligand. This leads to a hierarchy of families with a specified range of diversities, allowing
the best to be selected at a coarse level by evaluating energies of family heads. This also
leads to an ensemble of the best diversity families that are used for higher-level calculations.
The steps in GenMSCDock include bulky residue alanination, diversity finder, Voronoi
reclustering, side-chain refinement and neutralization.
1. Bulky residue alanination: To accommodate various orientations of the ligands,
all bulky residues (Phe, Trp, Tyr, Val, Ile, and Leu) were replaced by Ala.
2. Diversity finder: A critical part of GenMSCDock is to sample all binding
configurations in all potential binding sites and to group the results into families of
related structures allowing whole family to be rejected when the parent of a family
is weakly bound. The GenMSCDock method does two rounds, one to ensure
completeness and the other to enrich the better families. Based on our experiences,
a larger diversity parameter of 1.2 – 1.4 Å in the completeness step generates
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~2500 families. To achieve an average of 6 children in each family, we resort to
obtain 0.6 Å families in the enrichment step.
3. Voronoi re-clustering: As an enrichment step, Voronoi clustering fractionizes to
ensure that each family has the closest children within it. We find that with a 0.6 Å
diversity threshold all members of a family minimize to essentially the same
structure.
4. Side chain refinement: For each of the 10% low E conformation from Voronoi
clusters, we dealaninize the binding site with the ligand present using the SCREAM
procedure22. SCREAM finds the optimum side chain conformations for the bulky
residues compatible with each ligand configuration. After SCREAM, a short full
complex minimization is performed. Total 50% subset from our hierarchy was
selected for further steps.
5. Neutralization of charged groups: To remove the sensitivity of counter ions
distant from the active site, charged residues and ligands are modified by
protonating or deprotonated. This leads to a smoother electrostatic potential and
smaller solvation E difference in the binding site.
6. Relaxation: For each of the 50% ligand-side chain combination, we now define a
unified binding site and then minimize the atoms in the binding pocket. Then for
another 50% subset, we minimize the structure for the full ligand-protein complex
and pick a subset of 50% for annealing within 5 Å of the binding site.
7. Scoring E: GenMSCDock allows at each step for a percentage of the protein
+ligand complexes to be eliminated based on E criteria including continuum
solvent corrections. This improved procedure is now being automated to increase
the number of ligands for practical considerations. In each step, the complex was
scored using the following different E criteria.
* E scoring
- UnifiedCav (Unified cavity): the E from cavity analysis where all residues in the
unified cavity analysis contribute to the E.
- LocalCav (Local cavity): the normal version of cavity analysis where only residues
within the local 5.0Å binding cavity contribute to the E.
- Total: the MPSim E of the total complex (all atoms movable).
- FullSol (Full solvation E): the binding E with solvation for the complex, protein,
and ligand.
BE = (complexvac + complexsolv)−[(proteinvac + proteinsolv) + (ligandvac +
ligandsolv)]
- PartialSol (Partial salvation E): the binding E with solvation only for the ligand.
BE = complexvac − [proteinvac + (ligandvac + ligandsolv)]
- Interaction: the MPSim interaction E between the protein and ligand (protein fixed,
ligand movable).
3.2 Ensemble docking—The best ligand conformation from GenMSCDock matched
onto several low lying packing structures and relaxed the binding site to maximize the
interaction through the following sequential steps, BindsiteScream (SCREAM the 5 Å
binding site compatible with each ligand configuration), BindsiteMinimize (the 5 Å binding
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site minimization), iii) ComplexMinimize (full complex minimization), and BindsiteAnneal
(binding site annealing), and Neutralize including full complex minimization.
4. MD simulations in explicit membrane and water
To construct the periodic cell (73×70×71 Å) for the MD simulations, the predicted structures
of apohHT2BR, agonist (5-HT)-hHT2BR, and antagonist (2)-hHT2BR were each
independently embedded in the center of a square periodic lipid bilayer consisting of 100
palmitoyloleoyl phosphatidylcholine (POPC) molecules and solvated with 6,689 water
molecules. We used the CHARMM22 force field parameters for the protein, the TIP3 model
for water,38 and the CHARMM27 force field parameters for the lipids45. Quantum charges
from DFT/6311G** method were used for these ligands.
To compensate for the net charge of the protein and ligand, two waters for the apo-hHT2BR/
the antagonist-bound hHT2BR, three waters for the agonist-bound hHT2BR, and seven
waters for the antagonist-bound hHT2CR were replaced by chloride ions to attain a zero net
charge for the entire system. These systems contains 38,051 atoms (apo-hHT2BR), 38,977
atoms (5-HT-hHT2BR), 38,672 atoms (antagonist 1-hHT2BR, 38,818 atoms (antagonist 2-
hHT2BR), and 38,025 atoms (antagonist 1-hHT2CR and antagonist 2-hHT2CR).
The process was first to minimize the water, ion, and lipid bilayer while keeping the protein
and ligand fixed. This was followed by an all-atom conjugate gradient minimization of the
entire system for 1,000 steps. After this minimization, we carried out 500 ps of MD
simulations for equilibration with 1-fs time steps, followed by 1,000 steps of minimization
of the full system. Langevin dynamics was used for temperature control with the thermostat
set at 310 K. The Nose´–Hoover Langevin piston pressure control was used to control
fluctuations in the barostat, which was set at a pressure of 1 bar. Here the periodic cell was
constrained to remain orthorhombic, but the cell parameters were allowed to vary. A
dielectric constant of 1 was used for the electrostatic interactions, which were calculated by
using the particle mesh Ewald method.46 The grid in the x, y, and z directions used for the
particle mesh Ewald method was set at 72, 75, and 81 points, respectively. Every 10 ps a
snapshot was written to the trajectory file for subsequent analysis.
Seven independent 1ns MD simulations were carried out by using the program NAMD 2.6
for all minimization and MD runs.47 Three further 10 ns simulations were done for apo,
agonist-bound and antagonist 2-bound hHT2BR.
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Fig. 1.
The chemical structures of 5-HT2B receptor antagonists, 1, 2, 3, and agonist 4.
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Fig. 2.
The chemical structures of several SB-206533 1 derivatives. R5 lipophilic substituent is
surrounded by the aliphatic environments (V3.33, L3.29, I4.56, V4.60, M5.39, A5.46),
while R6 electron-withdrawing group is in the proximity of L3.29, S5.43, and N6.55.
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Fig. 3.
The binding site of the 5-HT2B receptor agonist, SNF 4, RNF, DesMeNF, and EthylNF.
Kim et al. Page 25
J Chem Inf Model. Author manuscript; available in PMC 2012 February 28.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig. 4.
Superimposition of the nonselective 5-HT2B/2C receptor antagonist (SB-206533 1) and the
selective 5-HT2B receptor antagonist (2) at the human 5-HT2B receptor. The N-methyl of
the cyclohexa indole ring of 2 is closer to the upper part of TM3 leading to unfavorable
interactions with bulkier Ile side chains in the 5-HT2C receptors (I132), while the methyl of
the cyclopenta-indole ring in SB-206533 1 is pointing toward the upper TM 4.
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Fig. 5.
The predicted structure of the highly potent and selective 5-HT2B receptor antagonist
PRX-08066 3.
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Fig. 6.
Water path (yellow arrow) of apo-protein, antagonist (2) and agonist (HT) bound 5HT2B
receptor complexes during 10 ns dynamics in explicit water and membrane. Ligands and
water in the 5 Å proximity of N172, D100, and N310 (NPxxY region) are displayed using a
space-filling model. The structure was taken from last trajectory of 10 ns dynamics.
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Fig. 7.
Trajectory analysis of salt-bridge interactions in the D(E)RY region (Left), the final hetero-
atom distance of human 5-HT2B receptor (hHT2BR) structures at 10 ns (Middle), and the
root mean square deviation (RMSD) of backbone in each TM (Right). Top) antagonist (2)-
hHT2BR, Middle) Apo-hHT2BR, Bottom) agonist (HT)-hHT2BR.
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Table 1
Cavity energy of several SB-206533 1 derivatives at human 5-HT2B and 2C receptors. The compound was
ordered by binding energy for 5-HT2C receptors. Experimental data (Pki) were taken from reference30.
5-HT2B 5-HT2C
# R5 R6 Pki UnifiedCav Pki UnifiedCav
46 SMe CF3 7.9 −47.53 8.6 −56.91
53 OiPr CF3 8.4 −51.39 8.5 −56.59
47 SEt CF3 8.0 −50.43 8.5 −55.19
48 SnPr CF3 7.8 −46.51 8.2 −54.57
56 SMe C2F5 7.5 −48.49 8.4 −54.09
36 tBu Cl 6.8 −41.67 7.7 −43.38
pKi, 5-HT2B: Binding affinity (human cloned receptors, HEK 293 cells, [3H]-5-HT)
pKi, 5-HT2C: Binding affinity (human cloned receptors, HEK 293 cells, [3H]mesulergine)
UnifiedCav: Unified cavity E (unit: kcals/mol)
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Table 2
The best 10 most stable packing structures of the human 5-HT2B receptor from CombiScream analysis.Total
energy (kcal/mol) = ScreamTot + MembSolE.
# H1 H2 H3 H4 H5 H6 H7 ScreamTot MembSolE Total E
1 0 0 0 0 0 0 0 605.0 97.6 507.4
2 0 0 0 330 0 0 0 679.5 −101.0 578.5
3 0 0 0 0 0 30 0 693.9 −102.9 591.0
4 0 0 0 0 0 30 330 694.3 −96.7 597.6
5 0 0 0 0 0 0 330 708.0 −99.8 608.2
6 210 0 0 0 0 0 0 737.4 −96.8 640.6
7 0 0 0 0 0 30 300 746.3 −89.6 656.7
8 0 0 0 30 0 0 0 755.3 −93.5 661.8
9 0 0 0 120 0 0 0 739.9 −76.1 663.8
10 0 0 270 0 0 0 0 744.6 −76.1 668.5
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